BI
BIAF.US bioAffinity Technologies, Inc.
- Market cap
- USD 4.15M
- P/E
- -
- P/B
- 1.09x
- ROE
- -418.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BIAF.US undervalued?
Graham numberThe Graham number of bioAffinity Technologies, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
bioAffinity Technologies, Inc. fundamental analysis
No fundamental analysis for bioAffinity Technologies, Inc. yet.
bioAffinity Technologies, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find c…
Full company profilebioAffinity Technologies, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
bioAffinity Technologies, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 1.31K | 4.80K | 2.53M | 9.36M | 6.16M | 5.24M |
| Gross Profit | -40.3K | -22.2K | -4.82K | 4.34K | 792K | 3.38M | 1.43M | -4.09M |
| Operating Income | -3.09M | -2.60M | -2.21M | -4.01M | -7.97M | -8.95M | -10.6M | -14.0M |
| EBITDA | -3.05M | -6.86M | -5.32M | -5.61M | -7.63M | -8.33M | -14.3M | -16.0M |
| Net Income | -3.31M | -7.27M | -6.33M | -8.15M | -7.94M | -9.04M | -14.9M | -16.4M |
| EPS | -202 | -443 | -1,044 | -816 | -408 | -335 | -130 | -18 |
| Balance Sheet | ||||||||
| Total Assets | 659K | 146K | 1.45M | 12.2M | 8.22M | 6.51M | 11.0M | 7.55M |
| Total Liabilities | 4.69M | 15.2M | 17.2M | 1.14M | 3.37M | 3.91M | 3.68M | 3.64M |
| Shareholders' Equity | -4.04M | -15.1M | -15.8M | 11.0M | 4.86M | 2.60M | 7.28M | 3.91M |
| Cash & Short-term Investments | 578K | 83.1K | 1.36M | 11.4M | 2.82M | 1.11M | 6.45M | 2.55M |
| Total Debt | 4.01M | 10.0M | 11.4M | 252K | 1.58M | 1.50M | 1.16M | 1.50M |
| Cash Flow | ||||||||
| Operating Cash Flow | -2.49M | -2.21M | -2.05M | -4.07M | -6.04M | -7.26M | -9.33M | -13.7M |
| Capital Expenditure | 11.4K | 2.89K | 2.00 | 220K | 22.9K | 79.1K | 60.6K | 230K |
| Free Cash Flow | -2.50M | -2.21M | -2.05M | -4.29M | -6.06M | -7.34M | -9.39M | -14.0M |
| Ratios | ||||||||
| ROE | - | - | - | -73.8% | -163.5% | -347.4% | -204.9% | -418.1% |
| ROA | -502.0% | -4,992.1% | -435.3% | -66.9% | -96.5% | -138.8% | -136.0% | -216.6% |
| Net Profit Margin | - | - | -484,411.4% | -169,771.2% | -313.5% | -96.6% | -242.0% | -312.1% |
| Debt to Equity | - | - | - | 0.02x | 0.33x | 0.58x | 0.16x | 0.38x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
bioAffinity Technologies, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 185.00 | 0.02 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:15 on Aug 24, 2026.
Who owns bioAffinity Technologies, Inc.
- Insiders 0.76%
- Institutions 5.28%
- Public & others 93.96%
- Shares outstanding 1.82M
- Free float 504K
Top funds holding BIAF.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 1.66K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 509.00 | 0.04% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 433.00 | 0.03% | -0.23% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 166.00 | 0.01% | -0.60% | Aug 2026 |
Top institutions holding BIAF.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sabby Management LLC | 366K | 1.90% | 0.00% | Jun 2026 |
| BlackRock Inc | 98.8K | 0.51% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 55.5K | 0.29% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 51.0K | 0.26% | +5.54% | Jun 2026 |
| J. Safra Sarasin Holding AG | 42.6K | 0.22% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 31.1K | 0.16% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 26.9K | 0.14% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 26.8K | 0.14% | 0.00% | Jun 2026 |
| State Street Corp | 24.1K | 0.13% | +67.43% | Jun 2026 |
| HRT FINANCIAL LLC | 20.8K | 0.11% | 0.00% | Jun 2026 |
| Northern Trust Corp | 16.7K | 0.09% | +31.61% | Jun 2026 |
| Virtu Financial LLC | 11.1K | 0.06% | 0.00% | Jun 2026 |
| Hanson Mcclain Inc | 10.0K | 0.05% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 6.48K | 0.03% | +214.20% | Jun 2026 |
| UBS Group AG | 4.20K | 0.02% | -54.37% | Jun 2026 |
| EMC Capital Management(TX) | 2.00K | 0.01% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 931.00 | 0.00% | 0.00% | Jun 2026 |
| IFP Advisors, LLC | 833.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.00 | 0.00% | 0.00% | Jun 2026 |
| Schonfeld Strategic Advisors LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
bioAffinity Technologies, Inc. company profile
- Company name
- bioAffinity Technologies, Inc.
- Ticker
- BIAF.US
- Exchange
- USA Stocks
- Listed since
- Sep 1, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 57
- Fiscal year end
- December
- Address
- 3300 Nacogdoches Road, San Antonio, TX, United States, 78217
- Phone
- 210 698 5334
- Website
- bioaffinitytech.com
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
bioAffinity Technologies, Inc. management
9- Mr. Steven GirgentiFounder & Executive Chairman of the Board · born 1946
- Ms. Maria Zannes J.D.Founder, President, CEO & Director · born 1956
- Mr. James Michael Edwards CPA, M.B.A.Chief Financial Officer · born 1967
- Mr. Xavier T. Reveles M.S.Chief Operating Officer · born 1969
- Dr. William Bauta Ph.D.Chief Science Officer
- Mr. Timothy P. Zannes J.D.Executive VP, Secretary & General Counsel · born 1953
- Ms. Julie Anne OvertonDirector of Communications
- Mr. Dallas J. ColemanVice President of sales
- Dr. Gordon Downie M.D., Ph.D.Chief Medical Officer